This site is intended for U.S. Healthcare Professionals.
ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Request a Rep
Be sure to bookmark or return to this page to remember these helpful resources.
How to order and access ONUREG®
Meet 2 types of patients you may see in your practice
ONUREG® transitions of care case study
ONUREG.com patient website
ONUREG® patient brochure
ONUREG® Spanish patient brochure
ONUREG® patient wallet cards